Abstract
The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Keywords: Refractory asthma, difficult asthma, segmentation, phenotypes, biomarkers, collaboration, symptomatic, moderate asthma, budesonide, therapeutics, Severe asthma, hypothesised, aetiology, sputum eosinophil, epigenetic, biological flui, prednisolone, Diseases Symposium, Cohort Studies
Current Pharmaceutical Design
Title: Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective
Volume: 17 Issue: 7
Author(s): Richard G. Knowles
Affiliation:
Keywords: Refractory asthma, difficult asthma, segmentation, phenotypes, biomarkers, collaboration, symptomatic, moderate asthma, budesonide, therapeutics, Severe asthma, hypothesised, aetiology, sputum eosinophil, epigenetic, biological flui, prednisolone, Diseases Symposium, Cohort Studies
Abstract: The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Export Options
About this article
Cite this article as:
G. Knowles Richard, Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective, Current Pharmaceutical Design 2011; 17 (7) . https://dx.doi.org/10.2174/138161211795429019
DOI https://dx.doi.org/10.2174/138161211795429019 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Signaling Networks as Targets for Pharmacological Intervention of Chronic Diseases
Current Signal Transduction Therapy Antioxidant Treatment and Endothelial Dysfunction: Is it Time for Flavonoids?
Recent Patents on Cardiovascular Drug Discovery Recent Patents on Stimuli Responsive Hydrogel Drug Delivery System
Recent Patents on Drug Delivery & Formulation Effects of Sublingual Immunotherapy on Allergic Inflammation: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Reflections on MicroRNAs in Chronic Pulmonary Disease: Looking into the miR-ror and Crystal Ball
Inflammation & Allergy - Drug Targets (Discontinued) Emerging Role of NF-κB in the Pathogenesis of Hepatic Encephalopathy
Current Signal Transduction Therapy Plant Natural Products as a Potential Source for Antibacterial Agents: Recent Trends
Anti-Infective Agents in Medicinal Chemistry More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design Assessment of Prescription Pattern in Asthma Therapy at Shamli Hospitals
Reviews on Recent Clinical Trials New Methods of Prevention and Treatment of Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies
Current Drug Therapy Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Recent Progress in the Discovery of Novel Glucocorticoid Receptor Modulators
Current Topics in Medicinal Chemistry Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry TNF-Alpha Antagonism in Severe Asthma?
Recent Patents on Inflammation & Allergy Drug Discovery Immunomodulation of the Allergic Inflammatory Response: New Developments
Inflammation & Allergy - Drug Targets (Discontinued) Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Current Molecular Medicine Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Cytokines as a Therapeutic Target for Allergic Diseases: A Complex Picture
Current Pharmaceutical Design